AbstractBackground: Vitiligo is considered an acquired autoimmune disorder characterized by depigmentation and white macules in the skin. It causes physical unhealthiness and mental breakdown in patients. Treatment involving oral medication, topical preparations, and phototherapy is available with a little application of microneedling to treat vitiligo.
Objective: The primary objective of this randomization clinical trial is to evaluate the effectiveness of microneedling over standard therapy in vitiligo patients.
Methods: 1.2 yearlong randomization trial conducted with 36 study subjects in the Department of Skin and Venereology, Dhaka National Medical Institute Hospital, Dhaka, Bangladesh. Two groups of patients participated in this trial where the study group of patients received standard therapy with microneedling and the control group of patients received standard treatment without microneedling. The primary outcome measure was the percentage of repigmentation assessed using clinical photographs and validated scoring systems at baseline, 1 week after 1st session, 2 weeks after 3rd session, and 1 month after 6th session. Result: Patients in the trial group showed a significant improvement (p<0.01) in pigmentation contrasted to the control group (p>0.01). Most of the study subjects were female (69%), and the male-female ratio was determined 1:2.24 in this study. 47.22% of healthy 16-30 years old patients participated in this study with other age groups. 50% of subjects are moderately satisfied with microneedling, where 17% of patients are completely satisfied, and 33% of dissatisfied patients identified by this study.
Conclusion: Microneedling is a painless invasive skin puncture procedure that makes it possible to transport the study drug to the inner binding surface directly. In comparison to the control group, the microneedling group of patients positively showed a notable recovery rate from vitiligo.
